Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 1.00 |
| ▸ | MMP9 | P14780 | 18/20 | 1.00 |
| ▸ | MMP14 | P50281 | 13/20 | 1.00 |
| ▸ | MMP3 | P08254 | 7/20 | 1.00 |
| ▸ | MMP8 | P22894 | 8/20 | 0.71 |
| ▸ | MMP7 | P09237 | 4/20 | 0.71 |
| ▸ | MMP1 | P03956 | 3/20 | 0.71 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247618 | 0.91 | MMP2 (0.84) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL2381073 | 0.88 | MMP2 (0.78) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL14727896 | 0.86 | MMP2 (0.76) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL10239054 | 0.86 | MMP2 (0.75) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL12717520 | 0.85 | MMP2 (0.74) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL19771706 | 0.84 | MMP2 (0.72) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL14730967 | 0.84 | MMP2 (0.72) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL314064 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL10238468 | 0.82 | MMP2 (1.00) | MMP2MMP9MMP14MMP3MMP8 | |
| SCHEMBL10187468 | 0.82 | MMP2 (0.76) | MMP2MMP9MMP14MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8828977-B2 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2012118498-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS, INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| EP-1986657-A2 | METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISC DISEASE USING A MATRIX METALLOPROTEASE INHIBITOR | Discogen, LLC (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007098099-A2 | METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISC DISEASE USING A MATRIX METALLOPROTEASE INHIBITOR | DISCOGEN, LLC (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070190149-A1 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2006125208-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | MMP2 3/4885MMP9 1/4885MMP14 15/4885 |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | MMP9, MMP10, MMP3 | MMP2 5/4885MMP9 1/4885MMP14 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.